Neue GPC entdeckt!

Vergleich zu GPC:
Umsatz GPC 29,73 Mio  18,73
Ebitda    -26,61 MIO - 2,00
Nettoverm.
je Aktie    1,38       2,17

Na, klingts nicht  gut?
Kurs ca. bei 10 Euro!
In Deutschland noch nicht endeckt!
Dafür umso regerer Handel in USA
Ist aber kein USA Wert!

Wenn das nicht gut klingT!

GPC hat in USA sich noch nicht  durchgesetzt!

sorry .. aber ich versteh gar nicht von was du da redest ?? gpc ?? .. oder ?? welche??

thx

Natürlich nicht GPC!

Morgen lüfte ich das Geheimnis!

Viel mir auf, weil starker Kursanstieg!

axo .. du wolltest nur kund tun, daß du was weißt was andere nicht wissen ??

tolle sache ... trotzdem viel glück ..

bleibt stehen, wenn nicht sogar unter!

Wert wird in Deutschlnd, Paris und als ADR WErt in USA gehandelt!

Nicht nur in Deutschland investieren, sondern auch über den Tellerrand "hinausgucken"
habe ich in eienm Anlegermagazin gelesen! Auch im Europ. Ausland.!
Leider findet man unter den US Seiten mehr über diesen Wert als in Deutsch!

Warum?
die Aktie ist charttechnisch, kurz, mittel und lanfristig absolut zu 100 % auf Buy eingestellt!

Rein techn. eine Kaufempfehlung!


Es gibt kaum noch Werte mit diesem Kriterium, die nicht IT Werte bzw. Tech Werte sind!

Dieser Wert ein Biotech Wert, ist vom Kurs noch nicht so aufgeblasen wie GPC, außerdem hat der WErt bei den letzen Zahlen weniger Verluste ausgewiesen als im Vorjahr!


Amerik. Kürzel ist:TRGNY
Dies ist der ADR Wert 1/3, also nicht wundern!

good trades
geldschneider

Transgene est une société de biotechnologie qui conçoit et développe des technologies et des produits de thérapie génique.
La thérapie génique consiste à insérer dans les cellules du patient, au moyen de gènes ou de vecteurs, des instructions génétiques pour la production de protéines thérapeutiques.
Transgene a d'ores et déjà développé 7 familles de vecteurs qu'il utilise dans les domaines de la cancérologie (cancer du poumon, cancer du sein, cancer du col de l'utérus, cancer de la prostate, etc.) et des maladies héréditaires (myopathie et mucoviscidose).
Le portefeuille de produits du groupe se compose de la façon suivante : 5 produits destinés au traitement du cancer à différents stades de développement et 1 produit de thérapie génique contre la myopathie en évaluations cliniques.       www.transgene.fr
hier auch auf englisch www.transgene.fr/us/?chapter=investor_relations
besonders interessant die Pipeline (man vergleiche mit GPC Biotech) www.transgene.fr/us/?chapter=product_pipeline
interessantes Mittel gegen häufige Unterleibs-Erkrankung in Phase 2 erfolgreich
www.bourse-de-paris.fr/nm/fr/pdf/...-03-2004%20MVA-HPV-IL2.pdf
der letzte Report v.11.2.war verbesserungsfähig
www.bourse-de-paris.fr/nm/fr/pdf/...%20financial%20results.pdf
besonders interessant scheinen die bisherigen Forschungsergebnisse zu einer Lungenkrebsimpfung in Phase 2 (zusammen mit Chemotherapie und Widerstandskraftverbesserung,wenn ich das richtig habe)
www.bourse-de-paris.fr/nm/fr/pdf/...9-02-2004%20MVA%20MUC1.pdf

bessere Infos noch unter www.bourse-de-paris.fr/fr/index_fs.htm?nc=2&ni=8&nom=marche  ganz unten mit Jahreschart etc

hat mich einfach interessiert,weil kaum jemand in Frankreich investiert ist

may be unable to conduct its clinical trials as quickly as it has predicted,
Transgene's clinical trials may not produce results sufficient to justify
further product development, Transgene may not have sufficient resources to
complete the research and commercialization of any of its product candidates,
competitors may develop technologies or products superior to Transgene's
technologies or products, Transgene may not be able to successfully enforce the
intellectual property rights in all jurisdictions relating to its product
candidates and other important factors described in Transgene's Annual Report on
Form 20-F for the year ended December 31, 2002 filed with the U.S. Securities
and Exchange Commission, including those factors described in the section
entitled "Risk Factors."

SOURCE Transgene



CONTACT:          Patrick Squiban, MD, VP Medical & Regulatory Affairs of

                 Transgene, +33-3-88-27-91-73; or Michael Long of Cohn & Wolfe,

                 +1-212-798-9775, for Transgene; or Estelle Guillot-Tantay or

                 Laurence Heilbronn, both of Image 7, +33-1-53-70-74-93, +33-1-53-70-74-64, for

                 Transgene

                 (TRGNY)

Mittel gegen Viren , Krebs

Transgene has five products in clinical development, two of which are
in Phase II clinical trials, two in Phase I/II and one that has completed Phase
I clinical trial. Transgene's proprietary vector technology platform consists of
adenovirus and poxvirus.


Na ich freue mich schon auf die Reise nach Frankreich zur HV!
jàime la france!

Schon vorbörslich über 2 % heute im Plus!

                                   Title:
"MVA-Muc1-IL2 vaccine immunotherapy for advanced non small cell lung cancer
                      (NSCLC): Interim Phase II Data"

                       Date and time of the session:
                     June 7, 2004 - 8:00 am to 12:00 pm


About Transgene

Transgene, based in Strasbourg, France, is a biopharmaceutical company dedicated to the discovery and development of therapeutic vaccines, immunotherapy products, and delivery technologies for the treatment of diseases for which there is no cure or adequate treatment at present, with a focus on the treatment of cancer. Transgene has five products in clinical development, two of which are in Phase II clinical trials, two in Phase I/II and one that has completed Phase I clinical trial. Transgene's proprietary vector technology platform consists of adenovirus and poxvirus.




--------------------------------------------------
Source: Transgene

and assess whether the treatment has sufficient activity against the disease to
warrant further development. The statistical hypothesis reflecting the chosen
lower and upper target response rates to be reached (20 and 40 percent,
respectively) requires at least five responses out of 18 patients in the first
stage, in order to proceed to the second stage, and 11 responses out of 33
patients at the end of the second stage. Enrollment is now complete.

The following responses were observed in the first 18 patients who received
upfront the combination of MVA-Muc1-IL2 with chemotherapy and have been
evaluated for response (stage 1 of the study):





    *  seven patients have responded to the treatment according to the RECIST

       criteria (partial responses, of which five have been validated to date

       in central review); and

    *  five patients had their disease stabilized for more than twelve weeks.

Together, these results indicate that 12 out of 18 patients have benefited from
the combination of MVA-Muc1-IL2 vaccination with chemotherapy. In the sub-group
of metastatic disease (14 patients with stage IV), 11 patients (79%) showed
clinical benefit (partial and stable diseases). Results from the ongoing stage 2
of the study are expected in the coming months.

Prostate cancer

The prostate cancer trial is evaluating MVA-Muc1-IL2 in patients who have had
primary local treatment by surgery or radiation and subsequently had progressive
elevation of their PSA (Prostate Specific Antigen) level without documented
evidence of metastatic disease, which suggests residual or recurrent prostate
cancer. There is increasing interest, as suggested by various publications and
meetings, to propose new treatments at this stage of rising PSA.

The trial is taking place in the United States as a Phase II multi-center,
randomized, open label trial to assess the clinical and biological effects of
two different vaccination schedules. The patients in the first arm receive a
weekly 108 pfu injection of MVA-Muc1-IL2 for six weeks and thereafter every
three weeks. Patients in the second arm receive the same treatment every three
weeks.

To date, 30 patients have been included and PSA data is available for 29 of them
to allow calculation of the change in the PSA doubling-time (PSA-DT) induced by
the vaccination. PSA-DT increased three-fold in patients receiving the weekly
injections and almost two-fold in patients receiving the three-week schedule.
Using a model-based analysis of the patient population, these changes in the
PSA-DT are highly significant with p

there is no cure or adequate treatment at present, with a focus on the treatment
of cancer. Transgene has five products in clinical development, two of which are
in Phase II clinical trials, two in Phase I/II and one that has completed Phase
I clinical trial. Transgene's proprietary vector technology platform consists of
adenovirus and poxvirus.

This press release contains forward-looking statements, including statements
regarding Transgene manufacturing capabilities. Statements that are not
historical facts are based on Transgene's current expectations, beliefs,
estimates, forecasts and assumptions, including Transgene's expectations related
to the reproducibility in humans of the preclinical results, progress in the
clinical trials and Transgene's belief as to the potential to successfully
manufacture products for the effective treatment of illness. The statements
contained in this release are not guarantees of future performance and involve
certain risks, uncertainties and assumptions which are difficult to predict.
Accordingly, actual outcomes and results may differ materially from what is
expressed in those forward-looking statements. Important factors which may
affect Transgene's future operating results include the following: Transgene's
product candidates may not demonstrate therapeutic efficacy after initial
promising results, Transgene may be unable to obtain regulatory approval for its
product candidates, Transgene may be unable to conduct its clinical trials as
quickly as it has predicted, Transgene's clinical trials may not produce results
sufficient to justify further product development, Transgene may not have
sufficient resources to complete the research, manufacturing and
commercialization of any of its product candidates, competitors may develop
technologies or products superior to Transgene's technologies or products,
Transgene may not be able to successfully enforce the intellectual property
rights in all jurisdictions relating to its product candidates and other
important factors described in Transgene's Annual Report on Form 20-F for the
year ended December 31, 2003 filed with the U.S. Securities and Exchange
Commission, including those factors described in the section entitled "Risk
Factors."

SOURCE Transgene



CONTACT:          Michel Hubert, VP Business Development, Transgene,

                 +33-3-88-27-91-12; Michael Long, Cohn & Wolfe, +1-212-798-9775; Estelle

                 Guillot-Tantay, +33-1-53-70-74-93, or Laurence Heilbronn, +33-1-53-70-74-64,

                 both of Image 7, for Transgene

                 (TRGNY)



www.prnewswire.com


Copyright (C) 2004 PR Newswire.  All rights reserved.

  View WatchList    Edit Watchlist     Symbol Search    Portfolio Tracker




TRANSGENE SA ADS - Nasdaq National Market: TRGNY

Chart Options    1 Day2 Day5 Day10 Day1 Month6 Month1 Year2 Year5 Year10 YearMax  BarDotLineMountain  

Printer friendly version)

Transgene: Cash Position and Net Cash Expenditures as of September 30, 2004

STRASBOURG, France, Nov 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- Transgene(Nasdaq: TRGNY; Nouveau Marche: FR0005175080) today announced cash position andnet cash expenditures for the third quarter and the nine months ended September30, 2004 (unaudited figures, USGAAP).Net cash expenditures amounted to euro 4.8 million (US$ 6.0 million) and euro14.9 million (US$ 18.5 million) for the third quarter and the first nine monthsof 2004, respectively. The net cash expenditures for the third quarter and thefirst nine months of 2003 amounted to euro 4.1 million (US$ 5.1 million) andeuro 13.8 million (US$ 17.1 million), respectively. The increase in net cashexpenditures in the first nine months of 2004 reflects a refund of research taxcredit of euro 0.2 million (US$ 0.2 million) in 2004 compared to euro 0.8million (US$ 1.0 million) in 2003 and a decrease of interest income due to lowercash held, cash outflows being unchanged.Cash and cash equivalents totaled euro 20.0 million (US$ 24.8 million) atSeptember 30, 2004. We believe that, based on our current estimates (coststructure, clinical development plans, operating revenues, capital expenditures... ), our cash position at September 30, 2004 will be sufficient to meet ourexpected financial requirements, including for our research and developmentactivities and our anticipated capital expenditures, through the end of July2005.Transgene also announced its decision to modify the content of its quarterlyfinancial communications. Because our research and development programs focus onthe mid- and long-term, we believe that the release of quarterly detailedfinancial results does not reflect this timing. As a result and as permitted byapplicable regulations and practices, we have decided to publish financial datafrom now on as follows:        Fiscal year and half year results: consolidated balance sheet,        statement of operations and net cash expenditures;        First and third quarters: consolidated net cash expenditures and        cash position.Transgene, based in Strasbourg, France, is a biopharmaceutical company dedicatedto the discovery and development of therapeutic vaccines, immunotherapyproducts, and delivery technologies for the treatment of diseases for whichthere is no cure or adequate treatment at present, with a focus on the treatmentof cancer. Transgene has five products in clinical development, two of which arein Phase II clinical trials, two in Phase I/II and one that has completed PhaseI clinical trial. Transgene's proprietary vector technology platform consists ofadenovirus and poxvirus.This press release contains forward-looking statements regarding Transgene'sfinancial requirements and expenditures. These statements are based onTransgene's current expectations, beliefs, estimates, forecasts and assumptionsand are not guarantees of future performance. Accordingly, actual outcomes andresults may differ materially from what is expressed. Important factors whichmay affect Transgene's future financial requirements and expenditures includethe following: regulatory approvals for product development and testing may besuspended or delayed, causing additional expenses to continue testing or obtaintesting rights; proceedings to obtain patents and litigation of third partyinfringement claims are expensive and could exceed anticipated budgets; rightsto proprietary genes and other technologies to further develop our business maybe more costly than anticipated; we may incur significant costs in connectionwith our product liability exposure; we may incur unanticipated costs inconnection with our use and handling of hazardous material; and other importantfactors described in Transgene's Annual Report on Form 20-F for the most recentfiscal year filed with the U.S. Securities and Exchange Commission, includingthose factors described in the section entitled "Risk Factors."Note: The official financial information of Transgene is stated in Euros. Thefinancial information expressed in US$ is translated solely for the convenienceof the reader at euro 1.00 = $ 1.2417, the noon buying rate of the FederalReserve Bank of New York on September 30, 2004.SOURCE TransgeneCONTACT:          Philippe Poncet, Chief Financial Officer of Transgene,                  +33-0-3-88-27-91-21; or Michael Long of Cohn & Wolfe, +1-212-798-9775; or                  Estelle Guillot-Tantay, +33-0-1-53-70-74-93 or Laurence Heilbronn,                  +33-0-1-53-70-74-64, both of Image 7URL:              http://www.transgene.fr http://www.prnewswire.comCopyright (C) 2004 PR Newswire.  All rights reserved.KEYWORD:          FranceINDUSTRY KEYWORD: HEA                  MTC                  BIOSUBJECT CODE

Transgene Moves Forward Its Vaccine Candidate MVA-HPV-IL2 In A Novel Approach Against Pre-Cancerous Cervical Lesions

STRASBOURG, France, Nov 30, 2004 /PRNewswire-FirstCall via COMTEX/ -- Transgene(Nasdaq: TRGNY; Euronext: FR0005175080) announced today that it is conducting anew Phase II clinical trial with its vaccine candidate MVA-HPV-IL2 in womendiagnosed with pre-cancerous lesions of the cervix (cervical intraepithelialneoplasia - CIN 2/3) related to type-16 human papillomavirus (HPV16). Based onthe favorable data obtained from the previous Phase II trial that was conductedon CIN 2/3, this newly approved trial will evaluate the efficacy of MVA-HPV-IL2after a 6-month observation period, which will give patients longer time tomount an immune response.The first Phase II trial included 31 patients with HPV16-related CIN 2/3, 29 ofwhich were evaluable for product efficacy. The patients were randomized into twosubgroups for the evaluation of two different doses (5.10(5) pfu and 5.10(7)pfu) of the vaccine candidate. Per the trial's protocol, the patients underwentsurgical removal of the lesions (conisation) six weeks after vaccination. Whileno indication of CIN 2/3 regression was shown in the patients treated with thelow dose of the vaccine, responses were documented after only six weeks in sevenout of 16 patients in the high dose group. Responses were measured in the formof lesion-grade or -size reduction through histology analysis (five patients)and/or viral clearance (four patients).The new trial is being conducted at six centers in France. Candidate enrollmentis on-going and preliminary data are expected during the second half of 2005. 18patients with HPV16-related CIN2/3 will receive three injections of thehigh-dose vaccine (5.10(7) pfu) administered sub- cutaneously. They will bemonitored every 2 months for 6 months with colposcopy, virology, cytology andpossibly histology controls. Only those still presenting with a CIN2/3 or an HPVinfection at the end of the 6-month period will undergo a conisation. The otherpatients will be considered as having responded to the therapeutic vaccinationand will not be considered to require conisation. They will continue to bemonitored to ensure that the regression is complete and long-lasting."Every year, 165,000 women in the U.S. and Europe are diagnosed withHPV16-related CIN 2/3," stated Dr. Patrick Squiban, Vice-President, Medical andRegulatory Affairs of Transgene. "We believe that an effective therapeuticvaccination against HPV16 constitutes a novel approach that may offer analternative to conisation in the future."About MVA-HPV-IL2 cancer vaccineTransgene's MVA-HPV-IL2 product candidate uses the MVA virus to carry andexpress two HPV antigens found in HPV 16, the E6 and E7 proteins. The newgeneration MVA vector is a highly attenuated poxvirus that combines theadvantages of a strain extensively tested in humans as a smallpox vaccine withthe ability to stimulate a strong immune response to antigens. The sequencecoding for the cytokine interleukin 2 (IL-2) is included to help stimulatespecific T cell responses.About TransgeneTransgene, based in Strasbourg, France, is a biopharmaceutical company dedicatedto the discovery and development of therapeutic vaccines, immunotherapyproducts, and delivery technologies for the treatment of diseases for whichthere is no cure or adequate treatment at present, with a focus on the treatmentof cancer. Transgene has five products in clinical development, two of which arein Phase II clinical trials, two in Phase I/II and one that has completed aPhase I clinical trial. Transgene's proprietary vector technology platformconsists of adenoviral and poxviral families.This press release contains forward-looking statements, including statementsregarding the efficacy and safety of and potential market for Transgene'sproduct candidates and prospects. Statements that are not historical facts arebased on Transgene's current expectations, beliefs, estimates, forecasts andassumptions, including Transgene's expectations related to progress in theclinical trials and Transgene's belief as to the potential of MVA-HPV-IL2 as atreatment against CIN 2/3 and HPV infection. The statements contained in thisrelease are not guarantees of future performance and involve certain risks,uncertainties and assumptions which are difficult to predict. Accordingly,actual outcomes and results may differ materially from what is expressed inthose forward-looking statements. Important factors which may affect Transgene'sfuture operating results include the following: Transgene may not havesufficient resources to complete on-going clinical trials and continue itsresearch and development activities after mid-2005, Transgene's productcandidates may not demonstrate therapeutic efficacy after initial promisingresults, Transgene may be unable to obtain regulatory approval for its productcandidates, Transgene may be unable to conduct its clinical trials as quickly asit has predicted, Transgene's clinical trials may not produce results sufficientto justify further product development, competitors may develop technologies orproducts superior to Transgene's technologies or products, Transgene may not beable to successfully enforce the intellectual property rights in alljurisdictions relating to its product candidates and other important factorsdescribed under "Risk Factors" and elsewhere in Transgene's Annual Report onForm 20-F for the year ended December 31, 2003 filed with, and in its Reports onForm 6-K furnished to, the U.S. Securities and Exchange Commission.SOURCE TransgeneCONTACT:          Patrick Squiban of Transgene, VP, Medical & Regulatory Affairs,                  +33-3-88-27-91-73; or Michael Long of Cohn & Wolfe, +1-415-365-8523, for                  Transgene; or Estelle Guillot-Tantay, +33-1-53-70-74-93, or Laurence                  Heilbronn, +33-1-53-70-74-64, both of Image 7, for Transgene                  (TRGNY)http://www.prnewswire.comCopyright (C) 2004 PR Newswire.  All rights reserved.KEYWORD:          FranceINDUSTRY KEYWORD: HEA                  BIO                  MTC

VectorVest Stock Analysis of Transgene ADR as of 2/1/2005

Thank you for requesting an analysis of Transgene ADR from VectorVest. The ticker symbol for Transgene ADR is TRGNY.  TRGNY is traded on the NASDAQ - (O)

Analysis Summary

TRGNY is overvalued compared to its Price of $2.98 per share, has somewhat below average safety, and is currently rated a Buy.

In-Depth Analysis

Business: TRANSGENE -SPON ADR, (TRGNY) Discovers and develops gene delivery technologies and gene therapy products and technologies for the treatment of acquired and inherited diseases for which there is no cure or adequate therapy.

Price: TRGNY closed on 2/1/2005 at $2.98 per share

Value: Value is a measure of a stock's current worth.  TRGNY has a current Value of $1.82 per share. Therefore, it is overvalued compared to its Price of $2.98 per share.  Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitability increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge.

RV (Relative Value): RV is an indicator of long-term price appreciation potential. TRGNY has an RV of 1.08, which is fair on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.

RS (Relative Safety): RS is an indicator of risk. TRGNY has an RS rating of 0.86, which is fair on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.

RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. TRGNY has a Relative Timing rating of 1.42, which is excellent on a scale of 0.00 to 2.00.  RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.

VST (VST-Vector):  VST is the master indicator for ranking every stock in the VectorVest database. TRGNY has a VST rating of 1.16, which is good on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price.

CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. TRGNY has a CI rating of 0.77, which is poor on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.

GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. TRGNY has a forecasted Earnings Growth Rate of 26.00%, which VectorVest considers to be excellent. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, (8.66%).

Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. TRGNY has a Buy recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.

Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position.  TRGNY has a Stop of $2.68 per share. This is $0.3 below TRGNY's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.

EPS (Earnings per Share):  EPS stands for leading 12 months Earnings Per Share.  TRGNY has a forecasted EPS of $-0.89 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.

P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings.  TRGNY has a P/E of -3.35. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 28.23. P/E is computed daily using the formula: P/E = Price/EPS.

EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. TRGNY has an EY of -29.93 percent. This is below the current average of 3.53% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).

GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. TRGNY has a GPE rating of -7.78.  High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 5.36%, the operative GPE ratio is 0.29. Therefore, TRGNY may be considered to be overvalued.

DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. TRGNY does not pay a dividend.

DY (Dividend Yield): DY reflects earnings per share as a percent of Price. TRGNY does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.

DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. TRGNY does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.

DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. TRGNY does not pay a dividend, so it does not have a Dividend Growth rating .

YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. TRGNY does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth.

Open: TRGNY opened trading at a price of $2.80 per share on 2/1/2005.

High: TRGNY traded at a High price of $2.98 per share on 2/1/2005.

Low: TRGNY traded at a Low price of $2.80 per share on 2/1/2005

Close: TRGNY closed trading at price $2.98 per share on 2/1/2005. (Close is also called Price in the VectorVest system)

Range: Range reflects the difference between the High and Low prices for the day. TRGNY traded with a range of $0.18 per share on 2/1/2005.

$Change: TRGNY closed up 0.28 from the prior day's closing Price.

%PRC: TRGNY's Price changed 10.33% from the prior day's closing price.

Volume: TRGNY traded 500 shares on 2/1/2005.

AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. TRGNY has an AvgVol of 7,300 shares traded per day.

%Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals 100 x (Volume/AvgVol). TRGNY had a %Vol of -93.15% on 2/1/2005

Sales: TRGNY has annual sales of $2,000,000

Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. TRGNY has a Sales Growth of 285.00% per year. This is excellent. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.

Sales Per Share (SPS): TRGNY has annual sales of $0.10 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.

Price to Sales Ratio (P/S): TRGNY has a P/S of 30.16. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.

Shares: TRGNY has 30,000,000 shares of stock outstanding.

Market Capitalization: TRGNY has a Market Capitalization of $89,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.

Industry Group: TRGNY has been assigned to the Drug (BiomedicalGenetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.

Business Sector: TRGNY has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.

The basic strategy of VectorVest is to buy Low risk, High reward stocks. We suggest that Prudent investors buy enough High Relative Value, High Relative Safety stocks to keep the overall RV and RS ratings of their portfolios above 1.00. As you do this, you'll find that your risk will go down and your investment performance will improve.

Graph

Transgene ADR members.vectorvest.com/newfsagraphs/TRGNY-2258top.png" style="max-width:560px" > members.vectorvest.com/newfsagraphs/TRGNY-2258bottom.png" style="max-width:560px" > Drug (BiomedicalGenetic) members.vectorvest.com/newfsagraphs/508-2258top.png" style="max-width:560px" > members.vectorvest.com/newfsagraphs/508-2258bottom.png" style="max-width:560px" >

FR 3,91 EUR

0,20 EUR

+5,39 %

Jetzt hab ich zwei schöne Biotechs im Depot: Transgene und A2PX9R
Wird wohl nach Bitcoins und Brennstoffzellen der neue Hype: Biotechs. Bin gespannt :-)

www.finanznachrichten.de/...olytic-virus-at-aacr-2022-004.htm